ATE456661T1 - Fusion von peptiden und proteinen mit thioredoxin und thioredoxin-ähnlichen molekülen - Google Patents

Fusion von peptiden und proteinen mit thioredoxin und thioredoxin-ähnlichen molekülen

Info

Publication number
ATE456661T1
ATE456661T1 AT02006660T AT02006660T ATE456661T1 AT E456661 T1 ATE456661 T1 AT E456661T1 AT 02006660 T AT02006660 T AT 02006660T AT 02006660 T AT02006660 T AT 02006660T AT E456661 T1 ATE456661 T1 AT E456661T1
Authority
AT
Austria
Prior art keywords
thioredoxin
molecule
protein
fusion
expression
Prior art date
Application number
AT02006660T
Other languages
English (en)
Inventor
John Mccoy
Edward R Lavallie
Original Assignee
Genetics Inst Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst Llc filed Critical Genetics Inst Llc
Application granted granted Critical
Publication of ATE456661T1 publication Critical patent/ATE456661T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5431—IL-11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02006660T 1991-02-06 1992-02-06 Fusion von peptiden und proteinen mit thioredoxin und thioredoxin-ähnlichen molekülen ATE456661T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65253191A 1991-02-06 1991-02-06
US07/745,382 US5270181A (en) 1991-02-06 1991-08-14 Peptide and protein fusions to thioredoxin and thioredoxin-like molecules

Publications (1)

Publication Number Publication Date
ATE456661T1 true ATE456661T1 (de) 2010-02-15

Family

ID=27096313

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02006660T ATE456661T1 (de) 1991-02-06 1992-02-06 Fusion von peptiden und proteinen mit thioredoxin und thioredoxin-ähnlichen molekülen
AT92907803T ATE237692T1 (de) 1991-02-06 1992-02-06 Fusionierung von peptiden und proteinen mit thioredoxin und thioredoxin-ähnlichen molekülen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT92907803T ATE237692T1 (de) 1991-02-06 1992-02-06 Fusionierung von peptiden und proteinen mit thioredoxin und thioredoxin-ähnlichen molekülen

Country Status (9)

Country Link
US (1) US5270181A (de)
EP (3) EP1231217B1 (de)
JP (1) JP2513978B2 (de)
AT (2) ATE456661T1 (de)
AU (1) AU663489B2 (de)
CA (1) CA2093643C (de)
DE (2) DE69233779D1 (de)
MX (1) MX9203295A (de)
WO (1) WO1992013955A1 (de)

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646016A (en) * 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
WO1993006116A1 (en) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
DE69333027T2 (de) * 1992-03-30 2004-05-06 Immunex Corp., Seattle Fusionsprotein , das zwei rezeptoren des tumornekrose-faktors enthält
FI931701A7 (fi) 1992-04-17 1993-10-18 Sankyo Co Rasvan muodostumista ehkäisevän tekijän johdannaiset, niiden valmistus ja käyttö
US6746859B1 (en) * 1993-01-15 2004-06-08 Genetics Institute, Llc Cloning of enterokinase and method of use
AU675506B2 (en) * 1993-01-15 1997-02-06 Genetics Institute, Llc Cloning of enterokinase and method of use
US5914254A (en) * 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US5635182A (en) * 1994-06-16 1997-06-03 Genetics Institute, Inc. Method of detecting ligand interactions
US6399296B1 (en) 1994-07-20 2002-06-04 The General Hospital Corporation Interaction trap systems for detecting protein interactions
ES2210306T3 (es) * 1994-07-20 2004-07-01 The General Hospital Corporation Sistemas de trampa para interacciones, para detectar interacciones de proteinas.
US5582821A (en) * 1994-07-22 1996-12-10 Genetics Institute, Inc. Methods for treating bleeding disorders
US5789199A (en) * 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5639635A (en) * 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US6274547B1 (en) * 1996-06-14 2001-08-14 Genetics Institute, Inc. Methods comprising the use of human interleukin-11 receptor proteins
DE69535274T2 (de) 1994-12-22 2007-06-06 Genetics Institute, LLC, Cambridge Verwendung eines menschlichen interleukin-11 rezeptors
US5935822A (en) * 1995-03-21 1999-08-10 The Regents Of The University Of Colorado Product and process for membrane and soluble polypeptide segregation
US6344343B1 (en) 1995-03-21 2002-02-05 The Regents Of The University Of Colorado Product and process for membrane and soluble polypeptide segregation
DE69637659D1 (de) * 1995-05-15 2008-10-09 Abbott Lab Verankerte expression heterologer proteine
US6352972B1 (en) 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US6126933A (en) * 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US6540993B1 (en) * 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6887461B1 (en) * 1998-10-26 2005-05-03 Genetics Institute, Llc Method of using IL-11 for treating mucositis
JP3092904B2 (ja) * 1995-10-13 2000-09-25 株式会社エイチ・エス・ピー研究所 細菌により可溶性蛋白質を生産する方法
SG49993A1 (en) 1995-12-28 1998-06-15 Fujirebio Kk Fused dna sequence fused protein expressed from said fused dna sequence and method for expressing said fused protein
AU2660397A (en) * 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US7655436B1 (en) 1996-04-30 2010-02-02 Schering Corporation Expression of soluble heterologous proteins in bacteria utilizing a thioredoxin/protein expression vector
WO1997041207A2 (en) * 1996-04-30 1997-11-06 Schering Corporation Expression of soluble heterologous proteins in bacteria utilizing a thioredoxin/protein expression vector
US7901910B2 (en) 1996-05-14 2011-03-08 Gregory Thomas Maine Embedded expression of insoluble heterologous proteins
US5858724A (en) * 1996-07-16 1999-01-12 Pel-Freez Recombinant rabbit tissue factor
US6815174B1 (en) * 1996-11-28 2004-11-09 Edgardo Poskus Thioredoxin-glutamate decarboxylase 65 fusion protein
US5831049A (en) * 1997-01-03 1998-11-03 Incyte Pharmaceuticals, Inc. Human thioredoxin
JP2001512306A (ja) * 1997-01-08 2001-08-21 ライフ テクノロジーズ，インコーポレイテッド タンパク質の産生方法
EP1911841B1 (de) * 1997-01-08 2015-06-03 Life Technologies Corporation Verfahren zur Herstellung von Proteinen
GB9703406D0 (en) 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6852508B1 (en) * 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US5989868A (en) 1997-09-12 1999-11-23 The Board Of Regents Of The University Of Oklahoma Fusion protein systems designed to increase soluble cytoplasmic expression of heterologous proteins in esherichia coli
WO1999015560A1 (en) * 1997-09-26 1999-04-01 Sloan-Kettering Institute For Cancer Research Soluble polypeptide having a delta-serrate-lag2 domain of delta homologue and uses thereof
WO1999024455A1 (en) 1997-11-10 1999-05-20 The General Hospital Corporation Detection systems for registering protein interactions and functional relationships
US6077689A (en) * 1997-12-24 2000-06-20 Amgen Inc. Enhanced solubility of recombinant proteins
KR100269671B1 (ko) * 1998-03-21 2000-10-16 박호군 면역 검출법을 이용한 hiv의 감염 억제 활성 물질의 검색방법 및 그에 사용되는 변이단백질
US6746852B1 (en) 1998-05-08 2004-06-08 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses thereof
US6733991B1 (en) 1998-05-08 2004-05-11 Osi Pharmaceuticals, Inc. AGS proteins and nucleic acid molecules and uses therefor
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
CA2334966A1 (en) * 1998-06-10 1999-12-16 William G. Tatton Screening method for dehydrogenase oligomerisation modulators
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
JP2002534059A (ja) * 1998-10-13 2002-10-15 ザ ユニバーシティ オブ ジョージア リサーチファウンデーション，インコーポレイティド 安定化された生物活性ペプチドおよび同定、合成および使用方法
US6387664B1 (en) * 1999-02-26 2002-05-14 Secretary Of Agency Of Industrial Science And Technology Sparc fusion protein and method for producing the same
US6953777B2 (en) * 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
EP1096948A4 (de) 1999-04-15 2004-04-07 Inst Genetics Llc Verwendung von interleukin-11 zur behandlung gastrointestinaler krankheiten
BR0012429A (pt) * 1999-07-15 2002-09-17 Genetics Inst Fórmulações para il-11
EP1360500B1 (de) * 2000-04-14 2010-01-13 Genencor International, Inc. Verfahren zur selektiven zielen
US7129326B2 (en) * 2000-04-14 2006-10-31 Genencor International, Inc. Methods for selective targeting
KR20020003917A (ko) * 2000-06-26 2002-01-16 복성해 꼬리 단백질과 인간 인터루킨-16의 융합 단백질, 이 융합단백질을 코딩하는 유전자, 이 유전자를 포함하는 발현벡터, 이 벡터로 형질전환된 대장균 및 이 대장균을이용한 인간 인터루킨-16의 생산 방법
US20030104570A1 (en) * 2000-06-26 2003-06-05 Cabezon Silva Teresa Elisa Virginia Triple fusion proteins comprising ubiquitin fused between thioredoxin and a polypeptide of interest
US6632638B1 (en) 2000-11-17 2003-10-14 Amgen, Inc. Enhanced solubility of recombinant proteins using Uracil DNA glycosylase inhibitor
ATE497603T1 (de) 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
US20020128190A1 (en) * 2001-03-09 2002-09-12 Leslie Lobel Expression of properly folded and soluble extracellular domain of a gonadotropin receptor
JP4838957B2 (ja) * 2001-05-02 2011-12-14 独立行政法人理化学研究所 無細胞タンパク質合成系を用いたタンパク質の製造方法
EP1572885A2 (de) * 2001-08-08 2005-09-14 Genzyme Corporation Verfahren zur behandlung von diabetes und anderer blutzuckerstörungen
US20040143104A1 (en) * 2001-08-08 2004-07-22 Wadsworth Samuel C. Methods of treating diabetes and other blood sugar disorders
AU2002362088A1 (en) * 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
US7858297B2 (en) * 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003051917A2 (en) * 2001-12-18 2003-06-26 Endocube Sas Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
US7081446B2 (en) * 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
EP1507003B1 (de) 2002-05-22 2011-09-21 Riken Verfahren zur proteinherstellung in einem zellfreien proteinsynthesesystem unter verwendung eines thioredoxinfusionsprotein-expressionsvektors
EP1551383A4 (de) 2002-06-24 2007-12-05 Paratek Pharm Innc VERFAHRN ZUR PRûVENTION UND BEHANDLUNG VON MIKROBIELLEN INFEKTIONEN DURCH MODULIERUNG VON TRANSKRIPTIONSFAKTOREN
CA2498931A1 (en) * 2002-09-16 2004-03-25 Wyeth Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
CN102584951A (zh) * 2002-11-25 2012-07-18 金克克国际有限公司 皮肤或毛发结合肽
JP4441170B2 (ja) * 2002-11-28 2010-03-31 独立行政法人理化学研究所 Ｓ１２リボソームタンパク質に変異を有する大腸菌細胞抽出液及びそれを用いる無細胞系によるタンパク質の製造方法
WO2004087917A1 (ja) * 2003-03-31 2004-10-14 National Institute Of Advanced Industrial Science And Technology チオレドキシン改変体
US20050107318A1 (en) * 2003-11-17 2005-05-19 Samuel Wadsworth Methods of treating diabetes and other blood sugar disorders
CA2576247C (en) 2004-08-26 2016-08-30 The University Of Western Ontario Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, in staphylococcus aureus
JP4590249B2 (ja) * 2004-11-17 2010-12-01 独立行政法人理化学研究所 糖タンパク質合成用の無細胞タンパク質合成システム
JP4868731B2 (ja) 2004-11-17 2012-02-01 独立行政法人理化学研究所 哺乳動物培養細胞由来の無細胞タンパク質合成システム
JP4787488B2 (ja) * 2004-11-19 2011-10-05 独立行政法人理化学研究所 直鎖状鋳型ｄｎａを用いた無細胞タンパク質合成方法及びそのための細胞抽出液
KR100699279B1 (ko) 2005-04-28 2007-03-23 학교법인 포항공과대학교 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법
BRPI0706818A2 (pt) * 2006-02-24 2011-04-05 Chiesi Farma Spa composições, métodos e usos de imunogênicos antiamilóides
EP1854455B1 (de) 2006-05-10 2009-10-07 Biocompatibles UK Limited GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung
WO2008042495A2 (en) 2006-07-21 2008-04-10 Life Technologies Corporation Sharply resolving labeled protein molecular weight standards
WO2008025564A2 (en) * 2006-08-31 2008-03-06 Nexigen Gmbh Methods for detecting protein-peptide interactions
US20100105612A1 (en) * 2006-10-11 2010-04-29 Oriental Yeast Co., Ltd. Agent containing fused protein of soluble rankl with epitope tag
US8226976B2 (en) * 2007-11-05 2012-07-24 Riken Method of using cell-free protein synthesis to produce a membrane protein
EA201071226A1 (ru) * 2008-04-25 2011-06-30 Мерк Патент Гмбх Искусственный каркас белка
AU2009246397B2 (en) 2008-05-13 2013-01-17 University Of Kansas Metal abstraction peptide (MAP) tag and associated methods
EP2145898A1 (de) 2008-07-15 2010-01-20 CHIESI FARMACEUTICI S.p.A. Antiamyloide immunogene Zusammensetzungen sowie entsprechende Verfahren und Anwendungen
EP2163243A1 (de) 2008-09-12 2010-03-17 Biocompatibles UK Limited Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern
FR2940292B1 (fr) * 2008-12-23 2013-05-10 Isp Investments Inc Peptides derives d'hmg-coa reductase et composition cosmetique et/ou pharmaceutique les contenant
PT104331A (pt) * 2009-01-13 2010-07-13 Escola Superior Agrária De Coi Protenas de fus†o, processo para a sua preparaã†o e sua utilizaã†o em sistemas de express†o de protenas recombinantes
KR101016766B1 (ko) * 2009-01-15 2011-02-25 한국과학기술연구원 티오레독신이 융합된 단백질 발현용 플라스미드 및 이를 이용한 목적 단백질의 생산방법
US20100209931A1 (en) * 2009-02-13 2010-08-19 Yolanda Sanchez Compositions for Identifying Novel Compositions for the Treatment of Disease and Methods of Using Same
EP2251028A1 (de) 2009-05-12 2010-11-17 Biocompatibles Uk Ltd. Behandlung von Augenerkrankungen unter Verwendung eingekapselter Zellen, die einen antiangiogenetischen Faktor und/oder einen neuroprotektiven Faktor codieren und sekretieren
CA2783968A1 (en) 2009-12-10 2011-06-16 Escola Superior Agraria De Coimbra Immunogens, process for preparation and use in systems of polyclonal antibodies production
WO2011151716A1 (en) * 2010-06-04 2011-12-08 Lupin Limited Process for the purification of recombinant human il-11
WO2011151721A1 (en) 2010-06-04 2011-12-08 Lupin Limited Process for production of fusion proteins using truncated e. coli thioredoxin
WO2011161244A1 (en) * 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
US20140004201A1 (en) 2010-09-15 2014-01-02 Biocompatibles Uk Ltd. Treatment of Vascular Diseases Using Encapsulated Cells Encoding and Secreting GLP-1, or a Fragment or Variant Thereof
EP2675899A4 (de) 2011-02-16 2014-09-10 Glycosyn LLC Biosynthese menschlicher milch-oligosaccharide in manipulierten bakterien
WO2013111754A1 (ja) 2012-01-23 2013-08-01 旭硝子株式会社 発現ベクターおよび蛋白質の製造方法
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
AR094276A1 (es) * 2012-12-21 2015-07-22 Alkem Laboratories Ltd Marcadores de fusion y sistema de vector de expresion para la expresion de hormona paratiroides humana (rhpth)
EP3194446B1 (de) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Zusammensetzungen und verfahren zur behandlung von fibrose
EP4194001B1 (de) 2015-04-22 2026-03-18 Cedars-Sinai Medical Center Enterisch verabreichte bittere oligopeptide zur behandlung von typ-2-diabetes und fettleibigkeit
US11618777B2 (en) 2015-07-31 2023-04-04 Shigeyuki Yokoyama Method of manufacturing membrane protein and utilization thereof
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
KR101962067B1 (ko) * 2018-04-23 2019-03-25 한림대학교 산학협력단 Txnl1 융합단백질을 포함하는 파킨슨병 예방 또는 치료용 약학 조성물
CN108912221A (zh) * 2018-07-31 2018-11-30 成都英普博集生物科技有限公司 用于生产重组融合蛋白的辅助蛋白、编码基因、重组融合蛋白、重组表达载体及制备方法
WO2021205027A1 (en) 2020-04-09 2021-10-14 Vaccibody As Individualized therapeutic anticancer vaccine
GB202400036D0 (en) * 2024-01-02 2024-02-14 Nicolson Tamara Therapy ii

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4745069A (en) * 1982-05-25 1988-05-17 Eli Lilly And Company Cloning vectors for expression of exogenous protein
FR2565163B1 (fr) * 1984-05-30 1989-04-07 Patterson Cy Nv Clavier a touches de commande manuelle combinees avec un systeme d'affichage
GB8518753D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Microbiological products
US4801536A (en) * 1985-10-11 1989-01-31 Genetics Institute, Inc. Method for producing heterologous proteins
DE3541856A1 (de) * 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
DE3545568A1 (de) * 1985-12-21 1987-07-16 Hoechst Ag Gm-csf-protein, seine derivate, herstellung solcher proteine und ihre verwendung
US4828988A (en) * 1986-05-15 1989-05-09 Smith Kline - Rit Hybrid polypeptides comprising somatocrinine and alpha1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
JPS6438099A (en) * 1987-04-07 1989-02-08 Agency Ind Science Techn Fused protein or dihydrofolate reductase and bradykinin
US5011772A (en) * 1988-02-05 1991-04-30 Public Health Research Institute Of The City Of N.Y. High yield protein production system
FR2649616B1 (fr) 1989-07-13 1991-10-18 C3P Seringue et aiguille d'injection a usage unique
EP0425821B1 (de) * 1989-09-29 1994-08-10 Ajinomoto Co., Inc. Verwendung von Human-ADF (=Adult T-cell leukemia-derived factor) zur Herstellung von Medikamenten
US5736363A (en) * 1991-07-29 1998-04-07 British Bio-Technology Limited IGF-II analogues
GB9120221D0 (en) * 1991-09-23 1991-11-06 Smithkline Beecham Biolog Novel compounds

Also Published As

Publication number Publication date
CA2093643C (en) 2001-10-30
DE69233008D1 (de) 2003-05-22
WO1992013955A1 (en) 1992-08-20
AU663489B2 (en) 1995-10-12
ATE237692T1 (de) 2003-05-15
US5270181A (en) 1993-12-14
EP1231217B1 (de) 2010-01-27
DE69233008T2 (de) 2004-01-22
EP1231275A2 (de) 2002-08-14
EP0574506B1 (de) 2003-04-16
JPH05507209A (ja) 1993-10-21
CA2093643A1 (en) 1992-08-07
MX9203295A (es) 1992-07-01
EP1231217A3 (de) 2004-01-21
JP2513978B2 (ja) 1996-07-10
EP0574506A1 (de) 1993-12-22
DE69233779D1 (de) 2010-03-18
AU1467192A (en) 1992-09-07
EP1231275A3 (de) 2004-01-21
EP1231217A2 (de) 2002-08-14

Similar Documents

Publication Publication Date Title
ATE237692T1 (de) Fusionierung von peptiden und proteinen mit thioredoxin und thioredoxin-ähnlichen molekülen
WO1995016044A3 (en) Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
DE60033293D1 (de) Neue b7-4 moleküle und deren verwendungen
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
ATE140973T1 (de) Ausscheidung von heterologen proteinen von e. coli
DE69634819D1 (de) Reguliertes autokrines wachstum von säugerzellen
DK0975755T3 (da) CRSP-protein (cysteinrige udskilte proteiner), nukleinsyremolekyler der koder herfor samt anvendelser deraf
WO2003042362A3 (en) PGC-1β, A NOVEL PGC-1 HOMOLOGUE AND USES THEREFOR
DK0434605T3 (da) Ny fremgangsmåde til fremstilling af ikke-fusioneret protein i E.coli
WO2001087978A3 (en) Human abc transporter and its use
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
DE68923006D1 (de) Fusionsproteine der untereinheit b von choleratoxin und eines heterologen antigens und dafür kodierende rekombinante nukleinsäure.
WO2002000718A3 (en) A human calcium channel protein and uses thereof
DK0805204T3 (da) Bitestikel - specifikt receptorprotein og anvendelse heraf
WO2002016589A3 (en) Human abc transporter family member and uses thereof
WO2000018923A3 (en) Slgp protein and nucleic acid molecule and uses therefor
WO2003020912A3 (en) Novel clark protein and nucleic acid molecules and uses therefor
AU6839900A (en) Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence
WO2001090146A3 (en) 57256 and 58289, human transporters and uses thereof
AU2002234132A1 (en) 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
WO2002051992A3 (en) 21163, a novel human prolyl oligopeptidase and uses therefor
WO2002006331A3 (en) 14087, a serine protease molecule and uses therefor
WO2002024913A3 (en) 32612, a novel human peptide transporter and uses therefor
WO2002000861A3 (en) Human beta-ketoacyl synthase (46619) and uses thereof
WO2002000841A3 (en) 58199, a membrane-associated protein and uses therefor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties